» Articles » PMID: 8794328

Abrogation of Growth Arrest Signals by Human Papillomavirus Type 16 E7 is Mediated by Sequences Required for Transformation

Overview
Journal J Virol
Date 1996 Oct 1
PMID 8794328
Citations 56
Authors
Affiliations
Soon will be listed here.
Abstract

Cells arrest in the G1 or G0 phase of the cell cycle in response to a variety of negative growth signals that induce arrest by different molecular pathways. The ability of human papillomavirus (HPV) oncogenes to bypass these signals and allow cells to progress into the S phase probably contributes to the neoplastic potential of the virus. The E7 protein of HPV-16 was able to disrupt the response of epithelial cells to three different negative growth arrest signals: quiescence imposed upon suprabasal epithelial cells, G1 arrest induced by DNA damage, and inhibition of DNA synthesis caused by treatment with transforming growth factor beta. The same set of mutated E7 proteins was able to abrogate all three growth arrest signals. Mutant proteins that failed to abrogate growth arrest signals were transformation deficient and included E7 proteins that bound retinoblastoma protein in vitro. In contrast, HPV-16 E6 was able to bypass only DNA damage-induced G1 arrest, not suprabasal quiescence or transforming growth factor beta-induced arrest. The E6 and E7 proteins from the low-risk virus HPV-6 were not able to bypass any of the growth arrest signals.

Citing Articles

Genome composition-based deep learning predicts oncogenic potential of HPVs.

Hao L, Jiang Y, Zhang C, Han P Front Cell Infect Microbiol. 2024; 14:1430424.

PMID: 39104853 PMC: 11298479. DOI: 10.3389/fcimb.2024.1430424.


A safe and potentiated multi-type HPV L2-E7 nanoparticle vaccine with combined prophylactic and therapeutic activity.

Zhao X, Zhang Y, Trejo-Cerro O, Kaplan E, Li Z, Albertsboer F NPJ Vaccines. 2024; 9(1):119.

PMID: 38926425 PMC: 11208501. DOI: 10.1038/s41541-024-00914-z.


CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.

Wang J, Calizo A, Zhang L, Pino J, Lyu Y, Pollard K Sci Adv. 2023; 9(47):eadg8876.

PMID: 38000020 PMC: 10672174. DOI: 10.1126/sciadv.adg8876.


CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon restoration of RB function in malignant peripheral nerve sheath tumors.

Wang J, Calizo A, Zhang L, Pino J, Lyu Y, Pollard K bioRxiv. 2023; .

PMID: 36778419 PMC: 9915673. DOI: 10.1101/2023.02.02.526674.


Human Papillomavirus 42 Drives Digital Papillary Adenocarcinoma and Elicits a Germ Cell-like Program Conserved in HPV-Positive Cancers.

Leiendecker L, Neumann T, Jung P, Cronin S, Steinacker T, Schleiffer A Cancer Discov. 2022; 13(1):70-84.

PMID: 36213965 PMC: 9827110. DOI: 10.1158/2159-8290.CD-22-0489.


References
1.
Halbert C, Demers G, Galloway D . The E7 gene of human papillomavirus type 16 is sufficient for immortalization of human epithelial cells. J Virol. 1991; 65(1):473-8. PMC: 240541. DOI: 10.1128/JVI.65.1.473-478.1991. View

2.
Hannon G, Beach D . p15INK4B is a potential effector of TGF-beta-induced cell cycle arrest. Nature. 1994; 371(6494):257-61. DOI: 10.1038/371257a0. View

3.
Munger K, Yee C, Phelps W, Pietenpol J, Moses H, Howley P . Biochemical and biological differences between E7 oncoproteins of the high- and low-risk human papillomavirus types are determined by amino-terminal sequences. J Virol. 1991; 65(7):3943-8. PMC: 241434. DOI: 10.1128/JVI.65.7.3943-3948.1991. View

4.
Chellappan S, Hiebert S, Mudryj M, Horowitz J, Nevins J . The E2F transcription factor is a cellular target for the RB protein. Cell. 1991; 65(6):1053-61. DOI: 10.1016/0092-8674(91)90557-f. View

5.
Firzlaff J, Luscher B, Eisenman R . Negative charge at the casein kinase II phosphorylation site is important for transformation but not for Rb protein binding by the E7 protein of human papillomavirus type 16. Proc Natl Acad Sci U S A. 1991; 88(12):5187-91. PMC: 51837. DOI: 10.1073/pnas.88.12.5187. View